<DOC>
	<DOCNO>NCT01693042</DOCNO>
	<brief_summary>Single repeat application autologous bone marrow-derived stem cell treat chronic post-infarction heart failure</brief_summary>
	<brief_title>Compare Effects Single Versus Repeated Intracoronary Application Autologous Bone Marrow-derived Mononuclear Cells Mortality Patients With Chronic Post-infarction Heart Failure</brief_title>
	<detailed_description>Improve mortality morbidity patient symptomatic chronic post-infarction heart failure full dose conventional medical device treatment include resynchronization therapy , single versus repeat intracoronary infusion autologous bone marrow-derived mononuclear cell .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<criteria>Previous myocardial infarction least 3 month ago , open infarct vessel bypass Left ventricular ejection fraction ( LVEF ) ≤ 45 % echocardiography Stable chronic heart failure NYHA class II III constant ( 4 week ) evidencebased optimal medical treatment age 18 80 year write informed consent woman childbearing age : negative pregnancy test ; effective contraception first 8 month trial Nonischemic cardiomyopathy Necessity revascularization vessel infarct vessel time study therapy Hemodynamic relevant severe valvular disease indication operative / interventional revision Heart failure preserve ejection fraction ( diastolic heart failure ) , LVEF &gt; 45 % Unstable Angina Severe peripheral artery occlusive disease ( ≥ Fontaine stadium III ) Active infection ( Creactive protein &gt; 10 mg/dl ) , chronic active hepatitis ; chronic inflammatory disease , HIV infection Neoplastic disease without document remission last 5 year Stroke ≤ 3 month Impaired renal function ( Serum creatinine &gt; 2,5 mg/dl ) time study inclusion Relevant liver disease ( GOT &gt; 2x upper normal limit , spontaneous INR &gt; 1,5 ) . Diseases hematopoetic system , anemia ( Hemoglobin &lt; 8.5 mg/dl ) , thrombocytopenia &lt; 100.000/µl ) Splenomegaly Allergy intolerance clopidogrel , prasugrel , ticagrelor , heparin , bivalirudin History bleed disorder gastrointestinal bleeding ≤ 3 month major surgery trauma ≤ 3 month Uncontrolled hypertension Pregnancy , lactation period mental retardation previous cardiac cell therapy within last 12 month Participation another clinical trial ≤ 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>heart failure</keyword>
	<keyword>old myocardial infarction</keyword>
	<keyword>bone marrow-derived mononuclear cell</keyword>
	<keyword>chronic</keyword>
	<keyword>ischemic</keyword>
</DOC>